Labcorp Holdings Inc. · NYSE:LH

Labcorp — Investor Presentation (June 2024)

21 slides from Labcorp's investor presentation, Jun 4, 2024

Slide 2: Cautionary statement regarding forward-looking statements
2 ©2024 Labcorp. All rights reserved. Cautionary statement regarding forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2024 guidance and related assumptions, (ii) the recently completed spin-o
Slide 3: Labcorp is the largest laboratory service provider in the world
3 ©2024 Labcorp. All rights reserved. Labcorp is the largest laboratory service provider in the world E X E C U T I N G O N G R O W T H S T R A T E G Y Leaders in science, technology and innovation focused on improving patient outcomes Driving profitable growth to generate consistent shareholder val
Slide 4: Strong underlying trends and market leadership drive significant growth
4 ©2024 Labcorp. All rights reserved. Strong underlying trends and market leadership drive significant growth E X E C U T I N G O N G R O W T H S T R A T E G Y Therapeutic advancement in complex disease states Earlier detection and diagnosis Precision medicine & companion diagnostics (CDx) Rapid inn
Slide 5: Labcorp is a mission driven, global laboratory services leader at scale
5 ©2024 Labcorp. All rights reserved. Labcorp is a mission driven, global laboratory services leader at scale E X E C U T I N G O N G R O W T H S T R A T E G Y Our mission Improve health, improve lives 100+ Countries where we support patients 6,500+ Unique tests available 600M+ Tests performed annua
Slide 6: Strong overlap with >50 years of healthcare laboratory services and innovation
Strong overlap with >50 years of healthcare laboratory services and innovation Market leadership across core laboratory service businesses Biopharma Laboratory Services (“BLS”) Diagnostics Laboratories (“Dx”) 6 ©2024 Labcorp. All rights reserved. E X E C U T I N G O N G R O W T H S T R A T E G Y
Slide 7: Best-in-class global lab operation with expansive footprint and scale
7 ©2024 Labcorp. All rights reserved. Best-in-class global lab operation with expansive footprint and scale E X E C U T I N G O N G R O W T H S T R A T E G Y United States and Canada Europe Geneva, Switzerland Mechelen, Belgium Harrogate, U.K. York, U.K. Shardlow, U.K. Huntingdon, U.K. Eye, U.K. Mü
Slide 8: Diagnostics Laboratories – leader in a highly fragmented market
8 ©2024 Labcorp. All rights reserved. Diagnostics Laboratories – leader in a highly fragmented market representing less than 5% of healthcare spend E X E C U T I N G O N G R O W T H S T R A T E G Y Diagnostics Market Positioned for growth with focused expansion through hospitals & local / regional l
Slide 9: Biopharma Laboratory Services
9 ©2024 Labcorp. All rights reserved. Biopharma Laboratory Services E X E C U T I N G O N G R O W T H S T R A T E G Y Note: FY 2023 revenue Pre-clinical early stage development work Laboratory services testing in support of phase I-IV trials Early Development Research Laboratories (ED) $16B Market O
Slide 10: Clear roadmap for sustainable profitable growth
10 ©2024 Labcorp. All rights reserved. Partner of choice for health systems & local / regional laboratories Lead in the development, licensing, & scaling of specialty testing including companion diagnostics Two significant near-term growth opportunities across biopharma and diagnostic laboratory ser
Slide 11: Partner of choice for health systems & local / regional laboratories
11 ©2024 Labcorp. All rights reserved. Partner of choice for health systems & local / regional laboratories E X E C U T I N G O N G R O W T H S T R A T E G Y Large market opportunity with robust pipeline and favorable trends for Labcorp Continuing consolidation across the industry 15 health system a
Slide 12: Lead in the development, licensing, and scaling of specialty testing
12 ©2024 Labcorp. All rights reserved. Lead in the development, licensing, and scaling of specialty testing E X E C U T I N G O N G R O W T H S T R A T E G Y Oncology Women’s Health Autoimmune Neurology Four specialty focus areas anticipated to grow at 9% CAGR Notable Recent Test Launches Vectra Lup
Slide 13: Agreement to acquire select assets of Invitae will enhance specialty testing
13 ©2024 Labcorp. All rights reserved. Agreement to acquire select assets of Invitae will enhance specialty testing at Labcorp1 E X E C U T I N G O N G R O W T H S T R A T E G Y a leader in genetic testing, rare diseases & data Market leader in hereditary cancer testing • 80% of National Cancer Inst
Slide 14: Invitae | Clear integration path to drive strong financial performance
14 ©2024 Labcorp. All rights reserved. Invitae | Clear integration path to drive strong financial performance E X E C U T I N G O N G R O W T H S T R A T E G Y Revenue of $275 - $300M in year 1 expected to grow approximately 10% annually EPS dilutive by 2 – 3% in year 1 and accretive by year 2 Earn
Slide 15: Outlook for 2024 as of April 25, 2024
15 ©2024 Labcorp. All rights reserved. Outlook for 2024 as of April 25, 2024 E X E C U T I N G O N G R O W T H S T R A T E G Y 1. 2024 Guidance includes an impact from foreign currency translation of 0.1% 2. Enterprise level revenue is presented net of intersegment transaction eliminations This guid
Slide 16: Our focus and strategy lead to sustainable profitable growth
16 ©2024 Labcorp. All rights reserved. Our focus and strategy lead to sustainable profitable growth E X E C U T I N G O N G R O W T H S T R A T E G Y $14B+ by 2026 5% - 8% revenue growth1 100 - 150 bps of margin expansion from 2023-2026 8.5% - 11.5% total adjusted EPS growth1 Annual free cash flow g
Slide 18: Track record of profitable growth
18 ©2024 Labcorp. All rights reserved. $9.1 $11.5 $13.1 $11.9 $12.2 $12.8 2019 2020 2021 2022 2023 2024 Guidance Midpoint (In Billions) Revenue Adjusted EPS Free Cash Flow (In Billions) 1 Track record of profitable growth E X E C U T I N G O N G R O W T H S T R A T E G Y 1 1 Diagnostics Biopharma La
Slide 19: 2023 – 2026 Outlook as of September 2023 Investor Day
19 ©2024 Labcorp. All rights reserved. 2023 – 2026 Outlook as of September 2023 Investor Day Metric Outlook Organic Revenue Growth 2026 CAGR vs 2023 Labcorp Enterprise 3.5% to 5.5%1 Diagnostics Laboratories 2.5% to 4.5%2 Biopharma Laboratory Services 4.5% to 7.5% Acquisition Revenue Growth Labcorp E
Slide 20: Disciplined capital deployment to drive shareholder value
20 ©2024 Labcorp. All rights reserved. Disciplined capital deployment to drive shareholder value E X E C U T I N G O N G R O W T H S T R A T E G Y 1. 2019 through 2023 includes total company sources of cash and capital allocation for total Labcorp (includes discontinued operations) Targeted Gross De

Labcorp Holdings — Investor Presentation (June 2024) on 6ix

Labcorp — Investor Presentation (June 2024)

Slide 1: Labcorp: Executing on Growth Strategy

Slide 2: Cautionary statement regarding forward-looking statements

Slide 3: Labcorp is the largest laboratory service provider in the world

Slide 4: Strong underlying trends and market leadership drive significant growth

Slide 5: Labcorp is a mission driven, global laboratory services leader at scale

Slide 6: Strong overlap with >50 years of healthcare laboratory services and innovation

Slide 7: Best-in-class global lab operation with expansive footprint and scale

Slide 8: Diagnostics Laboratories – leader in a highly fragmented market

Slide 9: Biopharma Laboratory Services

Slide 10: Clear roadmap for sustainable profitable growth

Slide 11: Partner of choice for health systems & local / regional laboratories

Slide 12: Lead in the development, licensing, and scaling of specialty testing

Slide 13: Agreement to acquire select assets of Invitae will enhance specialty testing

Slide 14: Invitae | Clear integration path to drive strong financial performance

Slide 15: Outlook for 2024 as of April 25, 2024

Slide 16: Our focus and strategy lead to sustainable profitable growth

Slide 17: Appendix

Slide 18: Track record of profitable growth

Slide 19: 2023 – 2026 Outlook as of September 2023 Investor Day

Slide 20: Disciplined capital deployment to drive shareholder value

Slide 21: Thank you